Patents Assigned to Tottori University
  • Patent number: 12089547
    Abstract: The present invention relates to isolated strains of Epichloƫ endophytes that form stable symbiotic associations with cereal grasses, particularly wheat, wherein the symbiotic associations are combinations of endophytes and host plants that are not found in nature The invention also relates to methods of identifying and/or selecting fungal endophytes that form stable symbiotic associations with wheat plants including methods of screening for fungal endophytes that form stable symbiotic associations with wheat plants, and to methods of screening for wheat plants that form stable symbiotic associations with fungal endophytes.
    Type: Grant
    Filed: February 15, 2023
    Date of Patent: September 17, 2024
    Assignees: Grasslanz Technology Limited, National University Corporation Tottori University, The Grains Research and Development Corporation
    Inventors: Wayne Roydon Simpson, Richard David Johnson, Hisashi Tsujimoto
  • Patent number: 12063913
    Abstract: This application provides: a non-human animal that comprises a mouse artificial chromosome comprising a human antibody heavy chain gene or gene locus, a human antibody light chain ? gene or gene locus, and/or a human antibody light chain ? gene or gene locus, and in which endogenous antibody genes or gene loci corresponding to at least 2 human antibody genes or gene loci have been knocked out, wherein the animal can be stably retained through generations and can produce human antibodies; a method for producing the non-human animal; and a method for producing human antibodies using the non-human animal.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: August 20, 2024
    Assignees: National University Corporation Tottori University, Trans Chromosomics, Inc.
    Inventors: Yasuhiro Kazuki, Satoshi Abe, Mitsuo Oshimura
  • Publication number: 20240269174
    Abstract: The present disclosure provides a composition comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and its use thereof.
    Type: Application
    Filed: February 9, 2023
    Publication date: August 15, 2024
    Applicants: Yamaguchi University, National University Corporation Tottori University
    Inventors: Koji Tamada, Yukimi Sakoda, Keishi Adachi, Takafumi Nakamura
  • Patent number: 11866483
    Abstract: [Problem] To provide a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cells having fibrosis-inhibiting activity, which are useful in regenerative medicine. [Solution] A medium containing IC-2 or a related compound is inoculated with mesenchymal stem cells or bone marrow mononuclear cells, and the cells are cultured for a prescribed period of time while the IC-2 or related compound is maintained at a constant concentration, thereby allowing a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cultured cells having fibrosis-inhibiting activity, to be obtained.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: January 9, 2024
    Assignees: KanonCure, Inc., National University Corporation Tottori University
    Inventors: Yohei Kono, Noriko Itaba, Goshi Shiota
  • Patent number: 11825817
    Abstract: In this application, the provided are: a Down syndrome rat model characterized in that a rat gene homologous to at least one gene present on a human chromosome 21 or fragment thereof is a trisomy and is transmittable to progeny; or a Down syndrome rat model characterized in that it comprises a human chromosome 21 or fragment thereof, or an exogenous rat chromosome or fragment thereof on which a rat gene homologous to the human chromosome 21 or fragment thereof is present, wherein at least one gene on the human chromosome 21 or fragment thereof or on the exogenous rat chromosome or fragment thereof is added to endogenous rat genes homologous to the at least gene so as to become a trisomy and to be transmittable to progeny: and a method for producing the Down syndrome rat model.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: November 28, 2023
    Assignees: National University Corporation Tottori University, Trans Chromosomics, Inc.
    Inventors: Yasuhiro Kazuki, Mitsuo Oshimura
  • Publication number: 20220313761
    Abstract: This invention provides a vaccinia virus that induces cell fusion between infected cells and a method for producing the same. Such vaccinia virus is deprived of the K2L gene or the HA gene or functions of the K2L gene and the HA gene and is mutated to induce cell fusion between infected cells and induce cell death.
    Type: Application
    Filed: May 12, 2020
    Publication date: October 6, 2022
    Applicants: National University Corporation Tottori University, Evolve Biotherapeutics Co., Ltd.
    Inventors: Takafumi Nakamura, Nozomi Kuwano, Motomu Nakatake, Hajime Kurosaki
  • Patent number: 11344589
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: May 31, 2022
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Takafumi Nakamura, Hajime Kurosaki, Motomu Nakatake
  • Publication number: 20220135602
    Abstract: Provided is a silyl ether-containing sulfonate salt that contains an anion represented by formula (1) and a cation. (In the formula, R1 to R4 are each independently a C1-4 alkyl group. m is an integer from 1 to 3. n is an integer from 2 to 8.
    Type: Application
    Filed: February 4, 2020
    Publication date: May 5, 2022
    Applicants: National University Corporation Tottori University, Nisshinbo Holdings Inc.
    Inventors: Masato Nanjo, Gen Masuda
  • Patent number: 11213527
    Abstract: A novel therapeutic drug for malignant tumors, cancer stem cells, or fibrosis is obtained. A therapeutic drug for malignant tumors or cancer stem cells is used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof. Alternatively, a therapeutic drug for fibrosis can be used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: January 4, 2022
    Assignees: National University Corporation Tottori University, KanonCure, Inc.
    Inventors: Goshi Shiota, Noriko Itaba, Keita Kanki, Kenzo Seto, Hiroki Shimizu, Yohei Kouno, Shinya Kunita, Zyunya Adumi, Tomohiko Sakabe, Kenichiro Abe, Minoru Morimoto, Hiroyuki Oka
  • Patent number: 10888594
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 12, 2021
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
  • Patent number: 10849946
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: December 1, 2020
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
  • Patent number: 10842431
    Abstract: A mental illness determination device includes a face change information acquisition unit and a mental illness determination unit. The face change information acquisition unit is configured to acquire face change information indicating a time-series change in face data of a subject when emotional stimulation information for stimulating any sense or any combination of senses among an auditory sense, an olfactory sense, a gustatory sense, a tactile sense, and a somatic sensation of the subject to change emotion, and is divided into positive information for increasing comfort and negative information for decreasing comfort is provided to the subject. The mental illness determination unit is configured to determine a state of mental illness of the subject on the basis of the face change information.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: November 24, 2020
    Assignees: Daikin Industries, Ltd., Tokyo Institute of Technology, National University Corporation Tottori University
    Inventors: Junichiro Arai, Akira Matsubara, Takahiro Hirayama, Hideki Hashizume, Takashi Gotou, Yasunori Kotani, Yoshimi Ohgami, Taro Tomatsu, Koichi Kaneko, Katsutoshi Yokoyama, Hiroshi Matsumura, Shenghong Pu, Masashi Itakura, Hiroaki Ohdachi, Masaru Ueki, Shinya Masuda
  • Publication number: 20200338149
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Application
    Filed: July 9, 2020
    Publication date: October 29, 2020
    Applicants: Astellas Pharma Inc., National University Corporation Tottori University
    Inventors: Shinsuke NAKAO, Tatsuya KAWASE, Takafumi NAKAMURA
  • Publication number: 20200289592
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Application
    Filed: April 30, 2020
    Publication date: September 17, 2020
    Applicants: Astellas Pharma Inc., National University Corporation Tottori University
    Inventors: Takafumi Nakamura, Hajime KUROSAKI, Motomu NAKATAKE
  • Patent number: 10758427
    Abstract: The present invention aims at providing a disposable diaper having excellent maintainability of a surface space and capable of being easily produced.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: September 1, 2020
    Assignees: Daio Paper Corporation, National University Corporation Tottori University
    Inventors: Bin Nakayama, Yoshiko Suyama, Kaori Fujii, Nobutada Nishiura, Aya Ohshima
  • Patent number: 10631759
    Abstract: According to an aspect, a testing instrument that is used for testing an airway protection function includes: a pipe portion continuous from an inlet port to an outlet port, the pipe portion having a plurality of holes penetrating the pipe portion from an outer surface of the pipe portion to an inner surface of the pipe portion, the holes being provided for guiding a reagent gas mixture to the inside of the pipe portion; and a guide portion covering all of the holes to form a closed space and guiding the reagent gas mixture to the closed space from an inflow port.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: April 28, 2020
    Assignees: National University Corporation Tottori University, Chest M.I., Incorporated
    Inventors: Kazunori Fujiwara, Katsuyuki Kawamoto, Masaru Ueki, Kazutake Uehara, Hiroya Kitano
  • Patent number: 10597398
    Abstract: To obtain a novel therapeutic drug for a malignant tumor or fibrosis. Used is a compound represented by formula (1), a salt thereof, or a solvate thereof. Also used is a therapeutic drug for a malignant tumor or a therapeutic drug for fibrosis, comprising a compound represented by formula (1), a salt thereof, or a solvate thereof.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: March 24, 2020
    Assignees: National University Corporation Tottori University, KanonCure, Inc.
    Inventors: Goshi Shiota, Noriko Itaba, Minoru Morimoto, Hiroyuki Oka, Kenichiro Abe, Hiroki Shimizu, Yohei Kouno, Satoshi Yokogi
  • Publication number: 20190367886
    Abstract: The present invention has an object to provide a vaccinia virus expressing a foreign gene and capable of killing cancer cells, and a cancer therapy drug comprising the vaccinia virus. The present invention relates to a vaccinia virus, wherein a suicide gene as a foreign gene selected from the group consisting of cytosine deaminase (CD) gene, uracil phosphoribosyltransferase (UPRT) gene, and herpes simplex virus thymidine kinase (HSV-tk) gene is introduced.
    Type: Application
    Filed: July 13, 2017
    Publication date: December 5, 2019
    Applicant: National University Corporation Tottori Tottori University
    Inventors: Takafumi Nakamura, Motomu Nakatake, Hajime Kurosaki, Kousuke Horita
  • Publication number: 20190336552
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Application
    Filed: April 8, 2019
    Publication date: November 7, 2019
    Applicants: Astellas Pharma Inc., National University Corporation Tottori University
    Inventors: Takafumi Nakamura, Hajime KUROSAKI, Motomu NAKATAKE
  • Patent number: 10370647
    Abstract: It is an object of the present invention to provide utilization of a UCA1 gene that is a host regulatory factor that enhances replication and/or propagation of a vaccinia virus, in order to effectively carry out cancer virotherapy using the vaccinia virus. The present invention relates to: a method for predicting and evaluating the cancer therapeutic effects of a vaccinia virus, which comprises measuring the expression of a UCA1 gene in the cancer cells of a cancer patient, and then predicting that a vaccinia virus exhibits cancer therapeutic effects on the patient, when the UCA1 gene has been expressed therein; and a vaccinia virus into which a UCA1 gene has been expressibly introduced.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: August 6, 2019
    Assignee: National University Corporation Tottori University
    Inventors: Takafumi Nakamura, Kousuke Horita, Hajime Kurosaki, Motomu Nakatake